

UNIONE EUROPEA Fondo Sociale Europeo Fondo Europeo di Sviluppo Regionale







Circulating tumor cells (CTCs) in NSCLC incorporate differential subsets including the epithelial-mesenchymal transition (EMT) phenotype

Lovero D¹, Mannavola F¹, Felici C¹, Cafforio P¹, Palmirotta R¹, Internò V¹, Calabrese C², Preste R², Santorsola M², Clima R², Attimonelli M² and Silvestris F¹.

1. Department of Biomedical Sciences and Clinical Oncology, University of Bari "Aldo Moro", Italy

2. Department of Biosciences, Biotechnology and Biopharmaceutics, University of Bari "Aldo Moro", Italy

BACKGROUND

Non-small cell lung cancer (NSCLC) is a major metastatic tumor for its ability to spread out and generate distant metastases. Recent evidence however suggests that the invasive phenotype of NSCLC is prevalently associated with the epithelial-to-mesenchymal transition (EMT) markers¹. This study was devoted to improve a DEPArray cell separation protocol by using EMT markers to isolate Circulating Tumor Cells (CTCs) for subsequent molecular analyses by NGS.

MATERIALS AND METHODS

Blood samples from 28 NSCLC patients were depleted of CD45pos leukocytes and stained with an antibody panel to EMT markers directed to EpCAM and E-Chaderin (epithelial) as well as CD-44, CD-146 and N-Chaderin (mesenkymal)². Cell sorting was performed by DEPArray equipment and the recruited CTCs were subjected in a limited number of patients (n=5) to NGS analysis avoiding previous whole genome amplification (WGA)³ with Ion AmpliSeq[™] Cancer Hotspot Panel v2 on the Ion Torrent PGM[™] system and compared to FFPE tumor tissue.

RESULTS

Four CD45neg cell subsets were identified in all patients (Fig. 1A), namely: 1) cells expressing only epithelial markers (E-CTC); 2) cells coexpressing both epithelial and mesenchymal markers (EM-CTC); 3) cells expressing only mesenchymal markers (MES-CTC); 4) cells negative for both phenotype markers (NEG-CTC). MES-CTC population was the most represented ($58.6\% \pm 2.8\%$) thus supporting the role of EMT in the early phase of tumor spreading (Fig. 1B). Total sequence variants identified by NGS in MES-CTCs were significantly higher than matched FFPE (84.4 ± 41.7 vs 20.4 ± 5.9 ; p<0.0001) (Fig.2A-B), revealing either inter- or intra-patient heterogeneity. Table 1 shows sequence variants with an allelic frequency threshold upper than 5%.



Gana	Patient #1		Patient #2		Patient #3		Patient #4		Patient #5	
Gene	FFPE	СТС	FFPE	СТС	FFPE	СТС	FFPE	CTC	FFPE	СТС
	c.4479G>A	c.4479G>A	c.4479G>A	c.4479G>A	c.4479G>A	c.4479G>A	c.4479G>A	c.4479G>A	c.4479G>A	c.4479G>A
APC	wt	wt	wt	c.4744G>C	wt	wt	wt	c.4744G>C	wt	wt
	wt	wt	wt	wt	c.4298C>T	wt	wt	wt	wt	wt
	wt	wt	wt	wt	wt	wt	wt	wt	wt	wt
	wt	wt	wt	c.8066A>G	wt	wt	c.5262G>T	c.5262G>T	wt	wt
	wt	wt	wt	wt	wt	c.5779A>G	wt	wt	wt	wt
ATM	wt	wt	wt	wt	wt	c.5805T>G	wt	wt	wt	wt
	wt	wt	wt	wt	wt	c.5820A>G	wt	wt	wt	wt
	wt	wt	wt	wt	wt	c.5829G>A	wt	wt	wt	wt
	wt	wt	wt	wt	wt	c.5785A>G	wt	wt	wt	wt
	wt	c.3578T>C	wt	wt	wt	wt	wt	wt	wt	wt
	wt	wt	wt	c.3836+7A>G	wt	wt	wt	wt	wt	wt
BRAF	wt	wt	wt	wt	wt	wt	wt	c.1355T>C	wt	wt
CDKN2A	wt	wt	wt	c.347A>G	wt	wt	wt	wt	wt	wt
	wt	wt) aut	wt) A / t	wt	c.890-7T>C		wt
CSFR1	c.*35_*36delC	c.*35_*36delC	vvi	vvi vvt	c.*35_*36delC	vvi vvt	c.*35_*36delC	c.*35_*36delC	vvi vvt	c.*35_*36delC
	AinsTT	AinsTT	vvi	ννι	AinsTT	ννι	AinsTT	AinsTT	vvi	AinsTT
	c.2361G>A	c.2361G>A	c.2361G>A	c.2361G>A	c.2361G>A	c.2361G>A	wt	wt	c.2361G>A	c.2361G>A
	wt	wt	wt	c.2625A>G	wt	wt	wt	wt	wt	wt
					c.2237_2251d		c.2237_2251d			
EGFR	wt	wt	wt	wt	elAATTAAGA	wt	elAATTAAGA	wt	wt	wt
	wt	wt	wt	wt	GAAGCAA	wt	GAAGCAA	wt	wt	
	wt	wt	wt	wt	wt	wt	wt		wt	c.2262A>G
					wt		wt	c.322A>G		wt
	c.421+58A>G	c.421+58A>G	wt	c.421+58A>G	wt	wt	wt	wt	c.421+58A>G	c.421+58A>G
	wt	wt	wt	C.729C>1	wt	WI	wt	wt	wt	wt
ERBB4	wt	wt	wt	wt	wt	C_2776_27790	wt	wt	wt	wt
	wt	wt	wt	wt	wt		wt	wt	wt	wt
	wt	wt	wt	wt	wt	C.2787C>T	wt	wt	wt	wt
) A/T) A/T) A/T) a/t) A/t	c 1776T>C) A/T) A/T	\A/t	\A/t
FBXW7	wt	wt	wt	wt	wt	c 1737G>A	wt	wt	wt	wt
	wt	wt	wt	wt	wt	c 1716T>C	wt	wt	wt	wt
	c.1953G>A	c.1953G>A	c.1953G>A	c.1953G>A	c.1953G>A	c.1953G>A	c.1953G>A	c.1953G>A	c.1953G>A	c.1953G>A
FGFR3	wt	wt	wt	wt	wt	wt	wt	wt	c.1959+22G>A	c.1959+22G>A
1	wt	wt	wt	wt	wt	wt	wt	wt	wt	wt
	c.1310-3T>C	c.1310-3T>C	c.1310-3T>C	c.1310-3T>C	c.1310-3T>C	wt	c.1310-3T>C	c.1310-3T>C	c.1310-3T>C	c.1310-3T>C
FLT3	c.2053+23A>G	c.2053+23A>G	wt	wt	wt	wt	wt	wt	wt	wt
	wt	wt	wt	c.1323G>A	wt	wt	wt	wt	wt	wt
GNAQ	wt	wt	wt	wt	c.671C>A	wt	wt	wt	wt	wt
HRAS	c.81T>C	c.81T>C	c.81T>C	c.81T>C	wt	wt	wt	wt	c.81T>C	c.81T>C
JACK3	wt	wt	c.2199+17C>T	c.2199+17C>T	wt	wt	wt	wt	wt	wt
	c.3849-24C>A	c.3849-24C>A	wt	wt	wt	wt	wt	wt	wt	wt
	4.4	wt	C.1416A>T	C.1416A>T	Wt	Wt	Wt	wt	Wt	Wt
KDR	wt	wi	wt	C 700 24>C	wt	0.790+54G>A	wt	wi	0.790+54G>A	0.790+54G>A
	vvi vvt	vvi vvt	vvi	C.799-2A>G	VVL	VVL vvt		VVL Vvt	vvi vvt	vvi vvt
		vvi vvt	vv t	vvi vvt	vv t va/t	vvi vvt	C.2013-30A>Cr	c 798 + 54G > 4	wt	wt
	wt wt	c 2483A>G	wt	wt	wt	wt	wt	wt	wt	wt
	wt	0.2400/42 C	wt	c.2507T>G	wt	wt	wt	wt	wt	wt
кіт	wt	wt	wt	c.2563T>C	wt	wt	wt	wt	wt	wt
	wt	wt	wt	wt	wt	wt	c.1621A>C	c.1621A>C	wt	wt
	wt	wt	wt	wt	wt	wt	wt	wt	wt	wt
	wt	wt	wt	wt	wt	wt	wt	wt	wt	c.136A>G
KDAS	wt	wt	wt	wt	c.37G>T	wt	wt	wt	wt	wt
NRAS	c.38G>A	wt	wt	wt	wt	wt	wt	wt	wt	wt
	wt	wt	wt	wt	wt	wt	wt	wt	c.34G>A	wt
				wt	c.534C>T	c.534C>T	c.534C>T	c.534C>T		
	wt	wt	wt	c.2518A>G		wt	\A/t	vart	wt	wt
	wt	wt	wt		wt	c.2460C>A	wt	wt	wt	wt
	wt	wt	wt	wt	wt	c.2469_2470d	wt	wt	wt	wt
	wt	wt	wt	wt	wt	elCCinsAA	wt	wt	wt	wt
MET	wt	wt	wt	wt	wt	c.2472_2473d	wt	wt	wt	wt
	wt	wt	wt	wt	wt	elGCinsAG	wt	wt	wt	wt
	wt	wt	wt	wt	wt	c.2454T>C	wt	wt	wt	wt
	wt	wt	wt	wt	wt	c.2484T>C	wt	wt	wt	wt
	wt	wt	wt	wt	wt	c.2487G>A	wt	wt	wt	wt
						c.2534T>A				
NRAS	Wt	Wt	Wt	Wt	Wt	C.51C>1	Wt	Wt	Wt	Wt
PDCERA	C.1701A>G	C.1701A>G	C.1701A>G	C.1701A>G	C.1701A>G	C.1701A>G	C.1701A>G	C.1701A>G	C.1701A>G	C.1701A>G
FUGERA	vvi vart	vvi	C.2472C>1	0.2472021	vvi vvi	vvi	vvl	wi	vv L vvrt	wt
	ννι		wt	vvi vvt	vvi vvt	vv t vv t	$c \frac{1173A>G}{c}$	c.20027002A	wt	wt
	wt	wt	c.352+40A>G	c.352+40A>G	wt	wt	c.352+40A>G	c.352+40A>G	c.352+40A>G	c.352+40A>G
	wt	wt	wt	c.1252-35T>C	wt	wt	wt	wt		wt
	vvi vvi	wi	wt	c.1252-17T>C	wt	wt	wt	wt	vvi	wt
	vvi vvt	vvi	wt	wt	wt	wt	wt	wt	vv L	c.1403A>G
	wit	vvi vvt	wt	wt	c.1173A>G	wt	wt	wt	\v/t	wt
.	wit	wt	wt	wt	wt	c.3081C>T	wt	wt	wt	wt
PIK3CA	wt	wt	wt	wt	wt	C.3054C>T	wt	wt	wt	wt
	wt	wt	wt	wt	wt	C.2221>C	wt	wt	wt	wt
	wt	wt	wit	wt	Wt		Wt	vvl	wt	wt
	wt	wt	vvl	wit	vvt	C 32660>0	wt	vvi vvi	wt	Wt
	wt	wt	۰۷۲ ۱۸/۲	wit	\v/t	C.3282C>T	wt w/t		wt	wit
	wt	wt	wt	wt	wt	c.3245C>T	wt	wt	wt	wt
	wt	wt	wt	wt	wt	c.3270G>A	wt	wt	wt	wt
	wt	wt	wt	c.717G>A	wt	wt	wt	wt	wt	wt
PTEN	wt	wt	wt	c.21G>A	wt	wt	wt	wt	wt	wt
	wt	wt	wt	c.19G>A	wt	wt	wt	wt	wt	wt
DB1	wt	wt	wt	c.2251T>C	wt	wt	wt	wt	wt	wt
	wt	wt	wt	c.1982G>A	wt	wt	wt	wt	wt	wt
	c.2307G>T	c.2307G>T	c.2307G>T	c.2307G>T	c.2307G>T	c.2307G>T	c.2307G>T	c.2307G>T	c.2307G>T	c.2307G>T
RET	wt	wt	wt	wt	wt	wt	wt	wt	c.2712C>G	c.2712C>G
	wt	wt	wt	wt	wt	wt	wt	wt	wt	c.1840G>T
1	Wt	Wt	Wt	C.1066C>1	Wt	wi	Wt	Wt	Wt	Wt
	C 955+58C>T	C 955+58C>T	vvl vvt	NVC N/t	0.1000G>C	vvi vvi	wt	vvi vvi	vvl vvt	vv t
SMAD4	wt	wt	wt	wt	wt	c.1062G>C	wt	wt	wt	wt
	wt	wt	wt	wt	wt	c 1332T>C	wt	wt	wt	wt
	wt	wt	wt	wt	wt	c.1233T>C	wt	wt	wt	wt
	wt	wt	wt	wt	wt	c.1218G>A	wt	wt	wt	wt
	wt	wt	wt	wt	wt	c.1035C>T	wt	wt	wt	wt
	wt	wt	wt	wt	wt	c.1089T>C	wt	wt	wt	wt
	wt	wt	wt	wt	wt	c.1059C>T	wt	wt	wt	wt
	wt	wt	wt	wt	wt	c.990A>G	wt	wt	wt	wt
	wt	wt	wt	wt	wt	c.1002G>A	wt	wt	wt	wt
						c.1353_1359de				
	wt	wt	wt	wt	wt	IGGCTACTinsA	wt	wt	wt	wt
				c 1225G>A		wt				
	wt	wt	wt		wt	c.1566G>A	wt	wt	wt	wt
SMO	wt	Wt	wt	wt	wt	c.1623G>A	wt	Wt	wt	wt
SINO	wt	wt	Wt	wt	Wt	c.1545T>C	Wt	wt	wt	wt
	wt	vvl	WL	wt	Wt	c.1590_1591d	wit	vvl	VVL	wt
	wt	wt	wt	Wt	Wt	elCGinsTT	wt	wt	wt	wt
	wt	wt	wt	c.961C>T	wt	wt	wt	wt	wt	wt
STK11	wt	wt	wt	wt	wt	c.465-51T>C	c.465-51T>C	c.465-51T>C	wt	wt
	wt	Wt	wt	wt	wt	Wt	wt	C.584 [>C	wt	wt
	Wt	Wt	Wt	C.391>C	wt	Wt	Wt	Wt	Wt	Wt
TDES	C.215C>G	C.215C>G	C.215C>G	C.215C>G	C.215C>G	C.215C>G	C.215C>G	C.215C>G	C.215C>G	C.215C>G
1893	wt	wit	wi	C.300C>A	Wt	vvl		0.3000>A	wi	wt
	vv t	VVL	vvt	vv t	vvt	vvi		vv t	vvt	





Figure 1. Phenotypic characterization of CTCs and enumeration. *A)* The analysis of EMT markers on CD45neg cells by DEPArray identifies four subsets of CTCs from patients with metastatic NSCLC. *B)* MES-CTCs are prevalent among other CTC phenotypic sub-groups.

A B 150-150-

Table 1. Comparison of sequence variants between CTCs and matched FFPE.Green: wild type; Yellow: neutral variants; Orange: uncertain pathogenicvariants; Red: pathogenic variants. According to: Cosmic, dbSNP and ClinVar



Figure 2. Number of sequence variants identified by NGS in CTCs and matched **FFPE samples.** *A) Box and whiskers plot* of total variants identified in CTCs and FFPE from 5 patients with NSCLC. B) Bar plot represents inter- and intra-patient heterogeneity relative to all variants identified for each patient in CTCs and FFPE.

CONCLUSIONS

Our data support the suitability of the liquid biopsy in NSCLC patients and confirm the intra-tumor heterogeneity occurring in different patients. Moreover, the classification of CTCs by EMT markers may characterize different CTC subsets that would be lost when using other CTC separation methods including the EPCAM-based recognition by CellSearch technology.

REFERENCE

1. Mahmood MQ. Epithelial mesenchymal transition (EMT) and non-small cell lung cancer (NSCLC): a mutual association with airway disease. Med Oncol 2017

2. Bulfoni M. In patients with metastatic breast cancer the identification of circulating tumor cells in epithelialto-mesenchymal transition is associated with a poor prognosis. Br Cancer Res 2016.

3. Palmirotta R. Next-generation Sequencing (NGS) Analysis on Single Circulating Tumor Cells (CTCs) with No Need of Whole-genome Amplification (WGA). Cancer Gen Prot 2017.